SCHEMBL18211419

SCHEMBL18211419

CC(C)Cc1ccc(C(=O)O)c(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ DNASE1L3 Q13609 1/20 0.57
▸ PRMT1 Q99873 1/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ ALPL P05186 1/20 0.56
▸ ALPI P09923 1/20 0.56
▸ ALPG P10696 1/20 0.56
▸ ATM Q13315 1/20 0.54
▸ PLEC Q15149 1/20 0.54
▸ CA9 Q16790 10/20 0.52
▸ CA1 P00915 8/20 0.50
▸ CA2 P00918 8/20 0.50
▸ CA12 O43570 4/20 0.50
▸ CA14 Q9ULX7 3/20 0.50
▸ ALB P02768 2/20 0.50
▸ CA7 P43166 3/20 0.49
▸ ESR1 P03372 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29668458 0.93 USP2 (0.68) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL18383481 0.93 USP2 (0.68) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL18211437 0.90 USP2 (0.48) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL24594128 0.89 USP2 (0.64) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL18754815 0.87 USP2 (0.62) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL22107769 0.87 USP2 (0.64) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL23762550 0.87 USP2 (0.57) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL22650188 0.86 USP2 (0.64) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL16231516 0.85 USP2 (0.64) USP2L3MBTL1DNASE1L3PRMT1MEN1
SCHEMBL20256560 0.85 USP2 (0.59) USP2L3MBTL1DNASE1L3PRMT1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11874280-B2 Use of divalent metals for enhancement of fluorescent signals Sony Group Corporation (JP) 2024-01-16 — — US disclosed
US-20210109104-A1 USE OF DIVALENT METALS FOR ENHANCEMENT OF FLUORESCENT SIGNALS Sony Group Corporation (JP) 2021-04-15 — — US disclosed
US-9932365-B2 Protein labeling with cyanobenzothiazole conjugates PROMEGA CORPORATION (US) 2018-04-03 — — US disclosed
US-20170283456-A1 PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-10-05 — — US disclosed
US-20160326576-A1 DUAL QUENCHER PROBES BIOSEARCH TECHNOLOGIES, INC. 2016-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326576-A1 DUAL QUENCHER PROBES DNA2, WRN, DDX42 USP2 2264/4885L3MBTL1 539/4885DNASE1L3 157/4885
US-20170283456-A1 PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES QPCTL, BCAT1, QPCT USP2 869/4885L3MBTL1 1238/4885DNASE1L3 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback